Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRBP |
---|---|---|
09:32 ET | 7382 | 20.6767 |
09:34 ET | 682 | 21.03 |
09:36 ET | 1054 | 21.04 |
09:38 ET | 2673 | 21.164 |
09:39 ET | 3796 | 21.1583 |
09:41 ET | 3993 | 21.4747 |
09:43 ET | 2938 | 21.615 |
09:45 ET | 4094 | 21.716929 |
09:48 ET | 4063 | 21.72 |
09:50 ET | 4054 | 21.8074 |
09:52 ET | 1651 | 21.775 |
09:54 ET | 7299 | 21.55 |
09:56 ET | 994 | 21.41 |
09:57 ET | 100 | 21.5 |
09:59 ET | 1049 | 21.4165 |
10:01 ET | 322 | 21.507 |
10:03 ET | 500 | 21.45 |
10:06 ET | 1380 | 21.465 |
10:08 ET | 300 | 21.48 |
10:10 ET | 607 | 21.59 |
10:12 ET | 1052 | 21.59 |
10:14 ET | 484 | 21.59 |
10:15 ET | 2350 | 21.44 |
10:17 ET | 3460 | 21.19 |
10:19 ET | 1967 | 21.136196 |
10:21 ET | 5030 | 20.86 |
10:24 ET | 3584 | 20.91 |
10:26 ET | 18938 | 20.97 |
10:28 ET | 6420 | 21.0862 |
10:30 ET | 1920 | 21 |
10:32 ET | 3500 | 20.9874 |
10:33 ET | 9443 | 21.07 |
10:35 ET | 1471 | 21.075 |
10:37 ET | 436 | 21.1085 |
10:39 ET | 5127 | 21.12 |
10:42 ET | 1225 | 21.08 |
10:44 ET | 200 | 21.24 |
10:46 ET | 711 | 21.245 |
10:48 ET | 1009 | 21.155 |
10:50 ET | 100 | 21.15 |
10:53 ET | 1204 | 21.13 |
10:55 ET | 400 | 21.12 |
10:57 ET | 200 | 21.1 |
11:00 ET | 1449 | 21.12 |
11:02 ET | 829 | 21.12 |
11:04 ET | 112 | 21.14 |
11:06 ET | 2355 | 21.24 |
11:08 ET | 3447 | 21.215 |
11:11 ET | 855 | 21.19 |
11:15 ET | 100 | 21.2 |
11:22 ET | 1960 | 21.1987 |
11:24 ET | 1346 | 21.22 |
11:26 ET | 2814 | 21.18 |
11:27 ET | 700 | 21.195 |
11:29 ET | 100 | 21.19 |
11:31 ET | 749 | 21.18 |
11:33 ET | 2001 | 21.2 |
11:36 ET | 1225 | 21.165 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 672.2M | -3.6x | --- |
Humacyte Inc | 671.6M | -4.3x | --- |
Scholar Rock Holding Corp | 685.9M | -3.9x | --- |
Savara Inc | 691.3M | -10.0x | --- |
ProKidney Corp | 692.3M | -3.2x | --- |
Rapport Therapeutics Inc | 695.0M | -12.1x | --- |
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $672.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 12.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.55 |
EPS | $-5.82 |
Book Value | $-1.56 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.